To investigate the efficacy of intravitreal injection of recombinant tissue plasminogen activator (rt-PA), ranibizumab, and gas without vitrectomy for submacular hemorrhage.

To elucidate the temporal relationship between detection of glaucomatous optic disc progression, as assessed by fundus photography, and visual field progression.

To compare diabetic retinopathy (DR) identification and ungradable image rates between nonmydriatic ultrawide field (UWF) imaging and nonmydriatic multifield fundus photography (NMFP) in a large multistate population-based DR teleophthalmology program.

Intraocular lymphomas (i-OL) are rare and aggressive subsets of primary cerebral tumors. Little is known about the pathogenesis. This is explained by the scarcity of patients and the tiny amount of ocular fluid sampled for biological analyses. In most cases, i-OL is misdiagnosed because its clinical features can mimic other ocular conditions. To date, no independent biological tool is able to firmly diagnose i-OL; the combination of cytologic examination, immunochemistry, flow cytometry, and molecular analysis is required.

Intraocular pressure, the only modifiable risk factor for glaucoma, is traditionally lowered with topical medication, laser or invasive surgery.1,2 More recently, there has been increased interest in alternative methods for lowering intraocular pressure through the use of minimally invasive extraocular drug delivery implants, such as punctual plugs, as well as more invasive surgical implants or intraocular injectable medication depots. The main goal of these alternative methods of drug delivery is to supplant the need for daily topical medication instillation that is associated with side effects and poor adherence.